US transparency proposals may hurt drug firms, industry warns
This article was originally published in Scrip
Executive Summary
The biopharmaceutical industry has expressed concern over draft proposals from the US FDA suggesting the agency discloses to the public information on drugs and biologics that have not yet been approved.